Application of liposomal technologies for delivery of platinum analogs in oncology

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3309-3319

  Liu, Demin ^a   He, Chunbai ^a   Wang, Andrew Z ^b   Lin, Wenbin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Drug delivery; Liposome; Platinum analog

Indexed keywords

CARBOPLATIN; CISPLATIN; DIMYRISTOYL PHOSPHATIDYLCHOLINE; DOXORUBICIN; EPTAPLATIN; GEMCITABINE; LIPLACIS; LIPOPLATIN; LIPOSOME; LIPOXAL; LOBAPLATIN; MITOPODOZIDE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

ABDOMINAL BLEEDING; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ENCAPSULATION; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INOPERABLE CANCER; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIPID COMPOSITION; LIPOSOMAL DELIVERY; LIVER METASTASIS; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OSTEOSARCOMA; OTOTOXICITY; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHILADELPHIA 1 CHROMOSOME; PHYSICAL CHEMISTRY; PROSTATE CANCER; REVIEW; SARCOMA; SPLEEN METASTASIS; STOMACH CANCER; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

CANCER; DRUG DELIVERY; LIPOSOME; PLATINUM ANALOG;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; HUMANS; LIPOSOMES; NANOCAPSULES; NEOPLASMS; PARTICLE SIZE; PLATINUM COMPOUNDS;

EID: 84883190208     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S38354     Document Type: Review

References (89)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573-584.
2. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205(4972):698-699.
3. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8(11):1777-1781.
4. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522-1534.
5. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev. 1999;99(9):2451-2466.
6. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007;107(5):1387-1407.
7. Welsh C, Day R, McGurk C, Masters JRW, Wood RD, Köberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer. 2004;110(3):352-361.
8. Köberle B, Masters JRW, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol. 1999;9(5):273-278.
9. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-320.
10. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract. 2011;2011:5.
11. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2008;6(1):1-18.
12. Boulikas T, Pantos A, Bellis E, Christofis P. Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther. 2007;5: 537-583.
13. Calvert A, Harland S, Newell D, etal. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140-147.
14. Wang X, Guo Z. Targeting and delivery of platinum-based anticancer drugs. Chem Soc Rev. 2013;42(1):202-224.
15. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010;39(35): 8113-8127.
16. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74(1-3):47-61.
17. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653-664.
18. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond). 2012;7(10):1577-1590.
19. Maeda H, Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv Drug Deliv Rev. 2011;63(3):129-130.
20. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1): 238-252.
21. Gregoriadis G, Swain CP, Wills EJ, Tavill AS. Drug-carrier potentialof lipsomes in cancer chemotherapy. Lancet. 1974;303(7870): 1313-1316.
22. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, etal. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.
23. Krasnici S, Werner A, Eichhorn ME, etal. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer. 2003;105(4):561-567.
24. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
25. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151(2): 201-215.
26. Bolotin EM, Cohen R, Bar LK, etal. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res. 1994;4(1): 455-479.
27. Mayer LD, Tai LCL, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta. 1990;1025(2):143-151.
28. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta. 1979;557(1):9-23.
29. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990;268(1):235-237.
30. Papahadjopoulos D, Allen TM, Gabizon A, etal. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88(24):11460-11464.
31. Bibi S, Lattmann E, Mohammed AR, Perrie Y. Trigger release liposome systems: local and remote controlled delivery? J Microencapsul. 2011;29(3):262-276.
32. Davidsen J, Jørgensen K, Andresen TL, Mouritsen OG. Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim Biophys Acta. 2003;1609(1):95-101.
33. Huang S-L, MacDonald RC. Acoustically active liposomes for drug encapsulation and ultrasound-triggered release. Biochim Biophys Acta. 2004;1665(1-2):134-141.
34. Smith B, Lyakhov I, Loomis K, etal. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2+ cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2+ affisomes). J Control Release. 2011;153(2):187-194.
35. Ahmad I, Longenecker M, Samuel J, Allen TM. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 1993;53(7):1484-1488.
36. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002;62(24):7190-7194.
37. Allen TM, Moase EH. Therapeutic opportunities for targeted liposomal drug delivery. Adv Drug Deliv Rev. 1996;21(2):117-133.
38. Gabizon A, Catane R, Uziely B, etal. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54(4): 987-992.
39. Safra T, Muggia F, Jeffers S, etal. Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2. Ann Oncol. 2000;11(8):1029-1033.
40. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. PEGylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007;18(7): 1159-1164.
41. Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134.
42. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
43. Vadiei K, Siddik Z, Khokhar A, Al-Baker S, Sampedro F, Perez-Soler R. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol. 1992;30(5):365-369.
44. Khokhar AR, Wright K, Siddik ZH, Perez-Soler R. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodecanoato trans-R, R-1,2 diaminocyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemother Pharmacol. 1988;22(3):223-227.
45. Han I, Ling Y-H, Al-Baker S, Khokhar AR, Perez-Soler R. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-r, r-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res. 1993;53(20):4913-4919.
46. Perez-Soler R, Lautersztain J, Stephens LC, Wright K, Khokhar AR. Preclinical toxicity and pharmacology of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum(II). Cancer Chemother Pharmacol. 1989;24(1):1-8.
47. Perez-Soler R, Yang LY, Drewinko B, Lauterzstain J, Khokhar AR. Increased cytotoxicity and reversal of resistance to cis-diamminedichloroplatinum(II) with entrapment of cis-bis-neodecanoato-trans-r, r-1,2-diaminocyclohexaneplatinum(II) in multilamellar lipid vesicles. Cancer Res. 1988;48(16):4509-4512.
48. Perez-Soler R, Khokhar AR, Lopez-Berestein G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexaneplatinum(II) encapsulated in multilamellar vesicles. Cancer Res. 1987;47(24Part 1):6462-6466.
49. Perez-Soler R, Lopez-Berestein G, Lautersztain J, etal. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R, R,-1,2-diaminocyclohexane platinum(II). Cancer Res. 1990;50(14):4254-4259.
50. Dragovich T, Mendelson D, Kurtin S, Richardson K, Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006;58(6):759-764.
51. Mori A, Wu S-P, Han I, Khokhar A, Perez-Soler R, Huang L. In vivo antitumor activity of cis-bis-neodecanoato-trans-R, R-l,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Cancer Chemother Pharmacol. 1996;37(5):435-444.
52. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, PEGylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43(1):1-7.
53. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs. 1999;10(10): 911-920.
54. Zamboni W, Gervais A, Egorin M, etal. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2004;53(4): 329-336.
55. Meerum Terwogt J, Groenewegen G, Pluim D, etal. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol. 2002;49(3):201-210.
56. Harrington KJ, Lewanski CR, Northcote AD, etal. Phase I-II study of PEGylated liposomal cisplatin (SPI-077 TM) in patients with inoperable head and neck cancer. Ann Oncol. 2001;12(4):493-496.
57. White SC, Lorigan P, Margison GP, etal. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006;95(7):822-828.
58. Seetharamu N, Kim E, Hochster H, Martin F, Muggia F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res. 2010;30(2):541-545.
59. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Deliv. 2012;2012:581363.
60. Veal GJ, Griffin MJ, Price E, etal. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer. 2001;84(8): 1029-1035.
61. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep. 2004;12(1): 3-12.
62. Devarajan P, Tarabishi R, Mishra J, etal. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res. 2004;24(4): 2193-2200.
63. Marr AK, Kurzman ID, Vail DM. Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs. Am J Vet Res. 2004;65(11):1474-1478.
64. Boulikas T. Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs. 2009;18(8): 1197-1218.
65. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. 2005;25(4):3031-3039.
66. Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol. 2011;68(4):945-950.
67. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. Liposomal oxaliplatin in the treatment of advanced cancer: a Phase I study. Anticancer Res. 2006;26(2B):1489-1493.
68. de Jonge MJ, Slingerland M, Loos WJ, etal. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur J Cancer. 2010;46(16):3016-3021.
69. Burger KN, Staffhorst RW, de Vijlder HC, etal. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med. 2002;8(1):81-84.
70. Khiati S, Luvino D, Oumzil K, Chauffert B, Camplo M, Barthélémy P. Nucleoside-lipid-based nanoparticles for cisplatin delivery. ACS Nano. 2011;5(11):8649-8655.
71. Aryal S, Hu C-MJ, Zhang L. Synthesis of Ptsome: a platinum-based liposome-like nanostructure. Chem Commun (Camb). 2012;48(20): 2630-2632.
72. Lee CM, Tanaka T, Murai T, etal. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res. 2002;62(15):4282-4288.
73. Suzuki R, Takizawa T, Kuwata Y, etal. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin PEG-liposome. Int J Pharm. 2008;346(1-2):143-150.
74. Rieter WJ, Taylor KM, An H, Lin W, Lin W. Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents. J Am Chem Soc. 2006;128(28):9024-9025.
75. Rieter WJ, Pott KM, Taylor KM, Lin W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc. 2008;130(35):11584-11585.
76. Taylor KM, Jin A, Lin W. Surfactant-assisted synthesis of nanoscale gadolinium metal-organic frameworks for potential multimodal imaging. Angew Chem Int Ed. 2008;47(40):7722-7725.
77. Liu D, Huxford RC, Lin W. Phosphorescent nanoscale coordination polymers as contrast agents for optical imaging. Angew Chem Int Ed. 2011;50(16):3696-3700.
78. Huxford RC, deKrafft KE, Boyle WS, Liu D, Lin W. Lipid-coated nanoscale coordination polymers for targeted delivery of antifolates to cancer cells. Chem Sci. 2012;3(1):198-204.
79. Liu D, Kramer SA, Huxford-Phillips RC, Wang S, Della Rocca J, Lin W. Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers. Chem Commun (Camb). 2012;48(21):2668-2670.
80. deKrafft KE, Boyle WS, Burk LM, Zhou OZ, Lin W. Zr-and Hf-based nanoscale metal-organic frameworks as contrast agents for computed tomography. J Mater Chem. 2012;22(35):18139-18144.
81. Huxford-Phillips RC, Russell SR, Liu D. Lipid-coated nanoscale coordination polymers for targeted cisplatin delivery. RSC Adv. 2013;3:14438-14443.
82. Batist G, Ramakrishnan G, Rao CS, etal. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19(5):1444-1454.
83. Berry G, Billingham M, Alderman E, etal. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998;9(7): 711-716.
84. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem. 1994;269(5): 3198-3204.
85. Banerjee G, Nandi G, Mahato SB, Pakrashi A, Basu MK. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J Antimicrob Chemother. 1996;38(1):145-150.
86. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998;58(15):3320-3330.
87. Kirpotin D, Park JW, Hong K, etal. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 1997;36(1):66-75.
88. Allen TM, Mehra T, Hansen C, Chin YC. Stealth liposomes: an improved sustained release system for 1-β-d-arabinofuranosylcytosine. Cancer Res. 1992;52(9):2431-2439.
89. Bally MB, Lim H, Cullis PR, Mayer LD. Controlling the drug delivery attributes of lipid-based drug formulations. J Liposome Res. 1998;8(3):299-335.